Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister SM, et al. Glioma Nat Rev Dis Primer. 2015;1(1):1–18.

Google Scholar 

Zuccato JA, Patil V, Mansouri S, Voisin M, Chakravarthy A, Shen SY, et al. Cerebrospinal fluid methylome-based liquid biopsies for accurate malignant brain neoplasm classification. Neuro-Oncol. 2023;25(8):1452–60.

Article  CAS  PubMed  Google Scholar 

Petrilli LL, Fuoco C, Palma A, Pasquini L, Pericoli G, Grabovska Y, et al. Inter and intra-tumor heterogeneity of paediatric type diffuse high-grade gliomas revealed by single-cell mass cytometry. Front Oncol. 2022;12:1016343.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Omuro A, Brandes AA, Carpentier AF, Idbaih A, Reardon DA, Cloughesy T, et al. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial. Neuro-Oncol. 2023;25(1):123–34.

Article  CAS  PubMed  Google Scholar 

Rong L, Li N, Zhang Z. Emerging therapies for glioblastoma: current state and future directions. J Exp Clin Cancer Res. 2022;41(1):142.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Richardson LG, Miller JJ, Kitagawa Y, Wakimoto H, Choi BD, Curry WT. Implications of IDH mutations on immunotherapeutic strategies for malignant glioma. Neurosurg Focus. 2022;52(2):E6.

Article  PubMed  Google Scholar 

Park JH, Lee HS, Choi JW, Lim SD, Koh HK, Cho KR, et al. Clinical Benefit of Bevacizumab and Irinotecan (BEV + IRI) in patients with Relapsed/Refractory glioblastoma (r/rGBM) and its potential predictors. Anticancer Res. 2022;42(12):6091–8.

Article  CAS  PubMed  Google Scholar 

Stock A, Hancken CV, Kandels D, Kortmann RD, Dietzsch S, Timmermann B, et al. Pseudoprogression is frequent after Front-Line Radiation Therapy in Pediatric Low-Grade Glioma: results from the German low-Grade Glioma Cohort. Int J Radiat Oncol Biol Phys. 2022;112(5):1190–202.

Article  PubMed  Google Scholar 

Liao D, Liu YC, Liu JY, Wang D, Liu XF. Differentiating tumour progression from pseudoprogression in glioblastoma patients: a monoexponential, biexponential, and stretched-exponential model-based DWI study. BMC Med Imaging. 2023;23(1):119.

Article  PubMed  PubMed Central  Google Scholar 

Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017;18(6):e315–29.

Article  PubMed  Google Scholar 

Alix-Panabières C, Pantel K. Liquid Biopsy: from Discovery to Clinical Application. Cancer Discov. 2021;11(4):858–73.

Article  PubMed  Google Scholar 

Bauman MMJ, Bouchal SM, Monie DD, Aibaidula A, Singh R, Parney IF. Strategies, considerations, and recent advancements in the development of liquid biopsy for glioblastoma: a step towards individualized medicine in glioblastoma. Neurosurg Focus. 2022;53(6):E14.

Article  PubMed  PubMed Central  Google Scholar 

Osti D, Del Bene M, Rappa G, Santos M, Matafora V, Richichi C, et al. Clinical significance of Extracellular vesicles in plasma from Glioblastoma patients. Clin Cancer Res. 2019;25(1):266–76.

Article  CAS  PubMed  Google Scholar 

Fiala C, Kulasingam V, Diamandis EP. Circulating Tumor DNA for early Cancer detection. J Appl Lab Med. 2018;3(2):300–13.

Article  CAS  PubMed  Google Scholar 

Corcoran RB, Chabner BA. Application of cell-free DNA analysis to Cancer Treatment. N Engl J Med. 2018;379(18):1754–65.

Article  CAS  PubMed  Google Scholar 

Fiala C, Diamandis EP. Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection. BMC Med. 2018;16(1):166.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Radu R, Petrescu GED, Gorgan RM, Brehar FM, GFAPδ:. A Promising Biomarker and Therapeutic Target in Glioblastoma. Front Oncol [Internet]. 2022 [cited 2022 Nov 9];12. https://www.frontiersin.org/articles/https://doi.org/10.3389/fonc.2022.859247.

van Asperen JV, Fedorushkova DM, Robe PAJT, Hol EM. Investigation of glial fibrillary acidic protein (GFAP) in body fluids as a potential biomarker for glioma: a systematic review and meta-analysis. Biomark Biochem Indic Expo Response Susceptibility Chem. 2022;27(1):1–12.

Google Scholar 

Ali H, Harting R, de Vries R, Ali M, Wurdinger T, Best MG. Blood-based biomarkers for glioma in the context of gliomagenesis: a systematic review. Front Oncol. 2021;11:665235.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hepner A, Porter J, Hare F, Nasir SS, Zetterberg H, Blennow K, et al. Serum neurofilament light, glial fibrillary acidic protein and tau are possible serum biomarkers for activity of Brain metastases and Gliomas. World J Oncol. 2019;10(4–5):169.

Article  PubMed  PubMed Central  Google Scholar 

Shrivastava R, Gandhi P, Gothalwal R. The road-map for establishment of a prognostic molecular marker panel in glioma using liquid biopsy: current status and future directions. Clin Transl Oncol off Publ Fed Span Oncol Soc Natl Cancer Inst Mex. 2022;24(9):1702–14.

CAS  Google Scholar 

Yadav N, Mishra K, B C AK, Singh D, Subberwal M. Clinical utility of serum glial fibrillary acidic protein in glial neoplasm. Surg Neurol Int. 2022;13:601.

Article  PubMed  PubMed Central  Google Scholar 

Ren AH, Diamandis EP, Kulasingam V. Uncovering the depths of the human proteome: antibody-based technologies for Ultrasensitive Multiplexed protein detection and quantification. Mol Cell Proteom MCP. 2021;20:100155.

Article  CAS  PubMed  Google Scholar 

Ghorbani A, Avery LM, Sohaei D, Soosaipillai A, Richer M, Horbinski C, et al. Discovery of novel glioma serum biomarkers by proximity extension assay. Clin Proteom. 2023;20(1):12.

Article  CAS  Google Scholar 

Berger TR, Wen PY, Lang-Orsini M, Chukwueke UN. World Health Organization 2021 Classification of Central Nervous System Tumors and implications for Therapy for adult-type gliomas: a review. JAMA Oncol. 2022;8(10):1493–501.

Article  PubMed  Google Scholar 

R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing: R Core Team. 2022. https://www.R-project.org/.

Ren AH, Soosaipillai A, Mathew A, Nikolenko G, Sardesai L, Stengelin M, et al. Utility of a fifth-generation ultrasensitive prostate-specific Antigen assay for monitoring prostate Cancer patients after Radical Prostatectomy with 3 years of Follow-Up. Clin Chem. 2020;66(10):1329–38.

Article  PubMed  Google Scholar 

Eklund E, Diamandis EP, Muytjens C, Wheeler S, Mathew A, Stengelin M, et al. Serum complexed and free prostate specific antigen levels are lower in female elite athletes in comparison to control women. F1000Research. 2017;6:1131.

Article  PubMed  PubMed Central  Google Scholar 

Diamandis EP, Stanczyk FZ, Wheeler S, Mathew A, Stengelin M, Nikolenko G, et al. Serum complexed and free prostate-specific antigen (PSA) for the diagnosis of the polycystic ovarian syndrome (PCOS). Clin Chem Lab Med. 2017;55(11):1789–97.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gandhoke C, Shah A, Singh D, Subberwal M, Gupta R, Gupta V, et al. Whether serum glial fibrillary acidic protein (GFAP) can be used as a diagnostic biomarker in patients with Glioblastoma? MAMC J Med Sci. 2020;6(1):27–27.

Article  Google Scholar 

Baumgarten P, Quick-Weller J, Gessler F, Wagner M, Tichy J, Forster MT, et al. Pre- and early postoperative GFAP serum levels in glioma and brain metastases. J Neurooncol. 2018;139(3):541–6.

Article  CAS  PubMed  Google Scholar 

Tichy J, Spechtmeyer S, Mittelbronn M, Hattingen E, Rieger J, Senft C, et al. Prospective evaluation of serum glial fibrillary acidic protein (GFAP) as a diagnostic marker for glioblastoma. J Neurooncol. 2016;126(2):361–9.

Article  CAS  PubMed  Google Scholar 

Vietheer JM, Rieger J, Wagner M, Senft C, Tichy J, Foerch C. Serum concentrations of glial fibrillary acidic protein (GFAP) do not indicate tumor recurrence in patients with glioblastoma. J Neurooncol. 2017;135(1):193–9.